anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: The aim of the study is to identify risk factors for the prognosis and survival of synchronous colorectal cancer and to create and validate a functional Nomogram for predicting cancer-specific survival in patients with synchronous colorectal cancer.
METHODS: Synchronous colorectal cancers cases were retrieved from the Surveillance, Epidemiology, and End Results database retrospectively, then they were randomly divided into training (n = 3371) and internal validation (n = 1440) sets, and a set of 100 patients from our group was used as external validation. Risk factors for synchronous colorectal cancer were determined using univariate and multivariate Cox regression analyses, and two Nomograms were established to forecast the overall survival and cancer-specific survival, respectively. We assessed the Nomogram performance in terms of discrimination and calibration. Bootstrap resampling was used as an internal verification method, and we select external data from our hospital as independent validation sets.
RESULTS: Two Nomograms are established to predict the overall survival and cancer-specific survival. In OS Nomogram, sex, age, marital status, ttumor pathological grade, AJCC TNM stage, preoperative serum CEA level, LODDS, radiotherapy and chemotherapy were determined as prognostic factors. In CSS Nomogram, age and marital status, AJCC TNM stage, tumor pathological grade, preoperative serum CEA level, LODDS, radiotherapy and chemotherapy were determined as prognostic factors.The C-indexes for the forecast of overall survival were 0.70, and the C-index was 0.68 for the training and internal validation cohort, respectively. The C-indexes for the forecast of cancer-specific survival were 0.75, and the C-index was 0.74 for the training and internal validation cohort, respectively. The Nomogram calibration curves showed no significant deviation from the reference line, indicating a good level of calibration. Both C-index and calibration curves indicated noticeable performance of newly established Nomograms.
CONCLUSIONS: Those Nomograms with risk rating system can identify high risk patients who require more aggressive therapeutic intervention and longer and more frequent follow-up scheme, demonstrated prognostic efficiency.
Chronic neutrophilic leukemia (CNL) is a rare type of myeloproliferative neoplasm (MPN). Due to its nonspecific clinical symptoms and lack of specific molecular markers, it was previously difficult to distinguish it from other diseases with increased neutrophils. However, the discovery of the CSF3R mutation in CNL 10 years ago and the update of the diagnostic criteria by the World Health Organization (WHO) in 2016 brought CNL into a new era of molecular diagnosis. Next-generation sequencing (NGS) technology has led to the identification of numerous mutant genes in CNL. While CSF3R is commonly recognized as the driver mutation of CNL, other mutations have also been detected in CNL using NGS, including mutations in other signaling pathway genes (CBL, JAK2, NARS, PTPN11) and chromatin modification genes (ASXL1, SETBP1, EZH2), DNA methylation genes (DNMT3A, TET2), myeloid-related transcription factor genes (RUNX1, GATA2), and splicing and RNA metabolism genes (SRSF2, U2AF1). The coexistence of these mutated genes and CSF3R mutations, as well as the different evolutionary sequences of clones, deepens the complexity of CNL molecular biology. The purpose of this review is to summarize the genetic research findings of CNL in the last decade, focusing on the common mutated genes in CNL and their clinical significance, as well as the clonal evolution pattern and sequence of mutation acquisition in CNL, to provide a basis for the appropriate management of CNL patients.
OBJECTIVE: To assess the prevalence of halitosis among the general population of Karachi, and to identify factors contributing to its occurrence.
METHODS: The cross-sectional study was conducted from March to July 2022 in Karachi after approval from the ethics review board of Dow University of Health Sciences, Karachi, and comprised the adult population of Karachi. Data was collected online using a questionnaire that was piloted before its link was distributed through social media platforms. The questionnaire evaluated the association of demographic features with self-perceived halitosis on the basis of which factors predictive of halitosis were determined. Data was analysed using SPSS 26.
RESULTS: Of a total of 342 subjects, 182(53%) were females and 160(47%) were males. There were 141(41$) subjects aged 18-25 years, and 166(48%) were graduates. Overall, 240(70%) subjects reported to have self-perceived halitosis. Age, monthly household income, niswar and tea consumption, irregular use of dental floss and tongue cleaning were associated with higher incidence of halitosis (p<0.05). Carrying water bottle while outside was associated with decreased halitosis (p=0.007). Symptoms of gastroesophageal reflux disease, sinusitis, asthma, diabetes, hypertension and mental stress were associated with halitosis (p<0.05). Higher monthly household income and daily use of dental floss predicted lower odds of halitosis (p<0.05).
CONCLUSION: Maintaining good oral hygiene and hydration reduced, while comorbid conditions increased the probability of halitosis.
Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Fludarabine will be given at a dose of 30 mg/m2/day IV over 30 mins for 5 doses. Cyclophosphamide will be given at a dose of 50 mg/kg/day IV over 2 hrs for 4 doses.
Daily transdermal nitroglycerin patch, starting at 0.2 mg/hr. Dose escalation up to 0.6 mg/hr.
Triphenyl phosphate (TPhP) is a tri-ester of phosphoric acid and phenol. It is used in products such as polyvinyl chloride, hydraulic fluids, polymers, photographic films and printed circuit cards as a flame retardant. It is also widely used in consumer products like electric and electronic devices, textiles and building necessaries. TPhP can diffuse into its surrounding environment easily, because it does not form a chemical bond with polymeric materials. Therefore, bio-monitoring of such compounds is needed for possible environmental and human health effects. In this study, we evaluated genotoxicity and cytotoxicity of TPhP on Allium cepa on the cells of root tips. A 10 mg/mL stock solution of TPhP was dissolved in DMSO and dilutions of 2, 4, 6, 8 and 10 mg/mL was made in distilled water. Onion bulbs, rooted in test tubes, were exposed to these concentrations of TPhP for 24 h. Distilled water was used as a negative control, 0.7% hydrogen peroxide was used as positive control, and 0.5% DMSO was used as solvent control. Significant inhibition of onion root growth was observed following treatment with the 6, 8 and 10 mg/mL TPhP ranges in comparison with the negative and solvent control groups (p < 0.05). Furthermore, in the TPhP treatment groups, total chromosome aberration ratios were significantly high in comparison with the controls (p < 0.05). These results suggest that TPhP have cytotoxic and genotoxic effects on A. cepa root tips.
A nutritional composition for infants delivered by Caesarean-section (C-Section) comprises human milk oligosaccharides (HMO) and milk fat globule membrane (MFGM). The composition also includes galacto-oligosaccharides (GOS) and/or polydextrose (PDX). The HMO is preferably present at about 0.5-10 mg/ml of the nutritional composition. The MFGM is preferably present at about 1.5-7.5 mg/ml of the nutritional composition. The GOS and/or PDX is preferably present at about 1-6 mg/ml of the nutritional composition. A method of promoting the growth of beneficial microbiota in the gastrointestinal tract of an infant delivered by C-section, and a method of modifying the ratio of Bacteroidetes to Firmicutes in an infant delivered by C-Section to resemble that of a breast-fed infant, comprising the step of providing the nutritional composition to the infant are also disclosed and claimed.
Patients will be divided into experimental and control groups by block randomization. No application will be applied to the experimental group for first night sleep. On the morning of the first night, patients' comfort levels and sleep quality will be measured by Visual Analogue Scale and Richard-Campbell Sleep Scale. The second night, an ergonomic sleep mask will be worn to this group. In the morning of the second night, patients' comfort and sleep quality will be measured with the same scales. The patients will be asked to sleep between 22.00 and 24.00 on the second night, and intensive care lights will decrease, the noise level will be minimized, and patients will not wake up during the night outside their treatment.
Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
This is a national multicenter randomized open-label superiority study of the use of Degarelix compared to LHRH agonists among men with advanced prostate cancer and pre-existing cardiovascular disease. Patients will be stratified based on baseline endothelial function and presence prostate cancer metastasis.

Study population: Subjects with pre-existing cardiovascular disease with locally advanced or metastatic prostate cancer and scheduled to start Androgen Deprivation Therapy (ADT). Patients already on ADT will be excluded. subjects will receive either two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months or an LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year. Follow-up visits will occur every 3 months. A blood sample for Prostate-specific antigen (PSA), cardiac biomarkers and rectal examination will be performed each visit. At baseline 6 and 12 months EndoPAT2000 measurements will be taken.
The present invention provides a method of reducing levels of at least one target protein in a cell. The cell is contacted with a first agent and a second agent. The first agent reduces synthesis of the target protein, e.g., by reducing levels of the mRNA of the target protein or inhibits translation of the mRNA. The second agent accelerates degradation of the target protein. The first agent may contact the cell before, after or simultaneously with the second agent. The first agent and the second agent may be in separate delivery vehicles, or in a single delivery vehicle. The first agent may be an RNAi (RNA interference) molecule, such as a small interfering RNA (siRNA), a small hairpin RNA (shRNA) or a microRNA (miRNA). The second agent may be a chimeric polypeptide containing a ubiquitin ligase polypeptide and a target protein interacting domain. The ubiquitin ligase polypeptide can be an E3 ubiquitin ligase, including, but not limited to, an SCF polypeptide, a HECT polypeptide and a UBRl polypeptide. In one embodiment, the SCF polypeptide is an F-box polypeptide.
The usual recommended dose of Ganite is 200 mg per square meter of body surface area (200 mg/m2) daily for 5 consecutive days. In patients with mild hypercalcemia and few symptoms, a lower dosage of 100 mg/m2/day for 5 days may be considered. If serum calcium levels are lowered into the normal range in less than 5 days, treatment may be discontinued early. The daily dose must be administered as an intravenous infusion over 24 hours. The daily dose should be diluted, preferably in 1,000 mL of 0.9% Sodium Chloride Injection USP, or 5% Dextrose Injection USP, for administration as an intravenous infusion over 24 hours. Adequate hydration must be maintained throughout the treatment period, with careful attention to avoid overhydration in patients with compromised cardiovascular status. Controlled studies have not been undertaken to evaluate the safety and effectiveness of retreatment with gallium nitrate.

When Ganite is added to either 0.9% Sodium Chloride Injection USP or 5% Dextrose Injection USP, it is stable for 48 hours at room temperature (15°C to 30°C) or for 7 days if stored under refrigeration (2°C to 8°C). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Evidence for the influence of the menstrual cycle (MC) phase on smoking cessation outcomes is contradictory and has been limited by small samples and a lack of clarity surrounding ideal quit date timing. Therefore, this large rigorously designed study aims to clarify whether targeting quit date to either the follicular or luteal phase of MC improves quit success. The primary hypothesis states that participants assigned a TQD in the follicular phase of their MC will be more likely to have quit successfully on day 7 of treatment than participants setting their own TQD (usual care). Quit rates at the end of treatment and 6 months post-TQD were identified as secondary objectives.

Participants will enroll in an online smoking cessation program providing nicotine replacement therapy (NRT) and behavioral support. Participants will receive a 6-week supply of NRT consisting of nicotine patch plus their choice of nicotine gum or lozenge, which the participants will be instructed to start on their target quit date (TQD). Eligible individuals will be randomized to a TQD: \[1\] during the mid-luteal phase of their MC (6-8 days pre-onset of menses), \[2\] during the mid-follicular phase of their MC (6-8 days post-onset of menses), or \[3\] within 30 days of enrollment with no regard to MC phase (usual care). Behavioural support will consist of a free downloadable app (My Change Plan) and brief videos delivered via e-mail. These videos will be produced by the CAMH Nicotine Dependence Service and will focus on health behavior change strategies such as building a quit plan, coping with cravings, and relapse prevention.
The Should I Screen print-based education (included with this IRB protocol) will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
The present invention discloses novel steroid mimics wherein a tri- or tetravalent phosphorous atom is isosterically substituted at any one of the seventeen positions occupied by the carbon atom in the steroidal skeleton, and wherein each adjacent position to the phosphorous is either unsubstituted or optionally substituted by nitrogen or an oxygen atom to satisfy the valency of said phosphorous atom. The invention is illustrated schematically below using both aromatic and non-aromatic steroids. Although the isosteric substitution (formulae 3, 4, 5, 6, 7, 8) phosphorous atom in the above structures (3-7) is indicated at 13, 14, and 17 positions, it is to be noted that the phosphorous can be substituted at any one of the seventeen positions in non­aromatic or eleven positions in aromatic steroids. The phosphorous atom may be trivalent or tetravalent, and may be radioactive or non-radioactive. The adjacent atoms, X, Y, or Z may be carbon, oxygen, or nitrogen. Other positions in the steroid mimics (3-8) may be optionally substituted alkyl, aryl, or other polar or non-polar functional groups to optimize biodistribution, receptor binding, and pharmacokinetic properties.
NEW MATERIAL:The safracin drivative of formula I (R is H or OH) or its acid addition salt. EXAMPLE:Dealanylsafracin A. USE:Antibacterial agent, antitumor agent and their intermediate. PROCESS:The compound of formula I can be prepared by reacting the compound of formula II (Safracin A or safracin B) with the compound of formula III (the phenyl ring A may have substitutent group selected from halogen such as Cl, Br, I, etc., NO2, lower alkyl such as methyl, ethyl, propyl, isopropyl, butyl, etc. and lower alkoxy such as methoxy, ethoxy, propoxy, butoxy, etc.), and treating the resultant compound of formula IV or its acid addition salt with an acid. The hydroxyl group of the compound of formula I or formula IV may be protected with acetyl group, etc.
This is a one-arm intervention study that includes assessments and questionnaires at several time points as early stage breast cancer patients undergo chemotherapy and at 6 months post-chemotherapy. Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits to evaluate engagement in physical activity. Study participants will complete questionnaires, an exercise log, and submit blood samples as multiple time points.
Previous interventions have not successfully increased physical activity levels in primary schools. This is arguably due to a lack of comprehensive data collection methods and the lack of co-involvement of teachers and children in intervention design. In previous research, accelerometers have been used by researchers to quantify children's physical activity levels. However, these have been research-grade devices which require a more complex analysis to extract results; because of this, these types of measurement tools have not been utilised by schools. This study will aim to utilise user-friendly technologies which can engage schools in the data collection process and be employed by schools to implement and measure strategies designed to increase physical activity by providing immediate feedback.

This project aims to investigate whether data from wearable technologies can be used to inform primary school-based practices and improve children's physical activity within school hours using co-developed interventions. This project is a participatory mixed-methods design in two phases. 7-9 schools will be recruited. The first phase in each school involves baseline measures of pupils' physical activity for 2-weeks, using accelerometers which have been specifically designed for school use. Pupils will be blinded to the physical activity data during this period. During this 2-week baseline teachers will be instructed to carry out lessons as normal, not changing their behaviour, or encouraging the pupils' physical activity. Data visualisations will be created from the 2-weeks of physical activity data collected within each school. Teachers will then be interviewed online, using Microsoft Teams, and encouraged to reflect on the physical activity data and co-develop 3-5 action points or strategies to increase children's physical activity. Teachers will then be asked to implement these action points over the subsequent 2-weeks, where again children's physical activity will be measured with the accelerometers. This time children will not be blinded to the data and can receive physical activity feedback if this is a strategy selected by their teacher. These changes will be at each schoolteacher's discretion and managed in a way they deem most appropriate. Following these 2-week changes teachers will be interviewed again about their experiences of using the technology and implementing strategies to encourage physical activity. They will then be shown similar data visualisations as before, comparing changes in pupils' physical activity between each 2-week period.
The post-mortem interval (PMI) is the time elapsed between the death of an individual and its forensic examination. It is a crucial information for judicial authorities, but current techniques still cannot establish a precise time interval. Novel approaches are therefore required. Recently, gingival tissue has emerged as interesting for forensic analysis thanks to the protection offered by lips to this tissue, limiting the influence of environmental factors. It is also easily accessible, and its sampling is minimally invasive even in the presence of rigor mortis. Moreover, the expression of HIF-1α, a master mediator of the hypoxic environment, has been described in gingival samples at different post-mortem (PM) times. We have hypothesized that the time-dependent post-mortem expression of HIF-1α could serve as a biomarker to more accurately predict the PMI. Our analyses were performed in an animal model, the mouse, where environment can be precisely controlled. Therewith, gingival tissue morphology was evaluated through histochemical staining and HIF-1α expression was analyzed by qPCR, western blots and immunofluorescence at different post-mortem times (0h to 100h). Our results showed (a) a global post-mortem stability of gingival tissue (b) a rapid increase in HIF-1α mRNA expression in the short post-mortem times followed by a slow decrease in transcript expression until 100h PM (c) an expression of the HIF- 1α protein and its degradation products, that follows the mRNA pattern (d) the presence of HIF-1α protein in the epithelial and connective layers of the tissue, with signal accumulation in both gingival strata until at least 32h post-mortem. This pilot study thus validated the mouse and the gingival tissue as models for post-mortem analyses, as well as for studying the fate of proteins such as HIF-1α. Transferring these approaches to human subjects may provide a more accurate estimate of PMI.
<P>PROBLEM TO BE SOLVED: To provide resolvin which is a biologically active medicinal agent functional in providing improved understanding of functions of physiological substances and eliminating or diminishing various disease states or conditions.  <P>SOLUTION: A new therapeutic agent generally termed resolvin is isolated. Resolvin is produced from a dietary omega-3 polyunsaturated fatty acid (PUFA) (e.g. eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA)), cyclooxygenase-II (COX-2) and an analgesic (e.g. aspirin (ASA)). Careful isolation of the compound produced from the combination of the components in an appropriate environment yields a di- and tri-hydroxy EPA or DHA compound having unique structural and physiological properties. An example of the compound is the one represented by the formula.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A medicine for treating cerebrovascular diseases belongs to a Chinese patent medicine. The existing medicine for treating cerebrovascular diseases has no obvious curative effect, only has the function of relieving and cannot radically cure the cerebrovascular diseases. The Chinese patent medicine of the invention consists of coptis, scutellaria, curcuma, realgar, cinnabar, borneol, storax, long-noded pit viper, bile, buffalo horn, bud powder, placenta, mustard seed and medlar. The Chinese patent medicine can radically cure hypertension and cerebrovascular diseases and has obvious curative effect on hemiplegia, rheumatic arthritis, quadriplegia pain and apoplexy. The medicine has the functions of promoting blood circulation, removing blood stasis, clearing pathogenic fire, removing toxic substance, inducing resuscitation, refreshing brain, eliminating thrombi, reducing blood lipid, dispelling pathogenic wind and dredging collaterals. The patients with hypertension and cerebrovascular disease can be cured completely in about one week.